July 25, 2016 — UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-based physician group in Central New Jersey, implemented UltraSPECT’s Xpress3.Cardiac solution at four of their sites. The sites include: Cardiology Associates of New Brunswick in New Brunswick, N.J.; Heart Specialists of Edison in Edison, N.J.; and New Brunswick Cardiology Group in their offices in Somerset and Monroe, N.J.
The software will benefit patient safety by reducing the dosage of injected radiopharmaceuticals, while lowering the radiation exposure for patients and nuclear staff alike. In addition, the technology saves valuable time for patients and staff, as it can produce the same high-quality single photon emission computed tomography (SPECT) images in less time than is typically required during standard exams.
“The image quality and clarity are remarkably good with UltraSPECT, which is particularly impressive when you consider that our scan time has been reduced by half in 80-90 percent of the cases,” said Jose Torres, technology director, New Brunswick Cardiology Group, Somerset, N.J. “UltraSPECT also helped us eliminate the two-day study protocol for heavier patients, who used to have to come back the next day for a stress test because the shorter scan times allow us to do more in the same visit. Patients are also more comfortable during the scan because they have to lay still for a shorter period of time.”
Torres also notes that the radiation exposure numbers on staff’s monthly dosimetry reports have been steadily going down after the UltraSPECT implementation. This is due to both reduced scan time and reduced doses needed for imaging tests.
All four installations are part of RWJPE’s radiopharmaceutical supply agreement with Nuclear Diagnostic Products (NDP). NDP delivers high-quality diagnostic and therapeutic radiopharmaceuticals to its customers and offers UltraSPECT products to facilities looking for a cost-effective solution to achieve faster and safer imaging while enhancing their diagnostic capabilities.
For more information: www.ultraspect.com
July 30, 2024 
